Prakash S Nagarkatti

US Patent:

8367415, Feb 5, 2013

Filed:

Sep 8, 2009

Appl. No.:

12/555128

Inventors:

Juhua Zhou - Lexington SC, US
Mitzi Nagarkatti - Columbia SC, US
Prakash Nagarkatti - Columbia SC, US

Assignee:

University of South Carolina - Columbia SC

International Classification:

C12Q 1/68
G01N 33/48

US Classification:

436 64, 436 63, 436 87, 436 94, 435 61, 435 611, 435 612, 435 614, 435 617, 536 231

Abstract:

A method for detecting a predisposition to breast cancer in a subject is provided. The method includes detecting in a biological sample from the subject one or more polymorphisms in the sequence of CD44 gene. The presence of one or more polymorphisms in the sequence of CD44 gene indicates that the subject has a predisposition for developing breast cancer.

US Patent:

8476074, Jul 2, 2013

Filed:

Jan 7, 2013

Appl. No.:

13/735320

Inventors:

Mitzi Nagarkatti - Columbia SC, US
Prakash Nagarkatti - Columbia SC, US

Assignee:

University of South Carolina - Columbia SC

International Classification:

G01N 33/48
C12Q 1/68

US Classification:

436 64, 436 63, 436 87, 436 94, 422430, 435 61, 435 611, 435 612, 435 614, 435 617, 435810, 536 231

Abstract:

A method for detecting a predisposition to breast cancer in a subject is provided. The method includes detecting in a biological sample from the subject one or more polymorphisms in the sequence of CD44 gene. The presence of one or more polymorphisms in the sequence of CD44 gene indicates that the subject has a predisposition for developing breast cancer.

US Patent:

20040259936, Dec 23, 2004

Filed:

Aug 13, 2004

Appl. No.:

10/497911

Inventors:

Leonard Nagarkatti - Richmond VA, US
Prakash Nagarkatti - Richmond VA, US
Robert McKallip - Richmond VA, US
Catherine Lombard - Richmond VA, US
Seongho Ryu - Richmond VA, US

International Classification:

A61K031/353

US Classification:

514/453000

Abstract:

A method of treating a patient in need of therapy for an abnormality of cells of the immune system is provided comprising administration of a therapeutically effective dose of a compound having CB2 cannabinoid receptor activity. The abnormality is particularly a malignancy such as a leukemia or lymphoma.

US Patent:

20090005461, Jan 1, 2009

Filed:

Jun 18, 2008

Appl. No.:

12/141634

Inventors:

Prakash S. Nagarkatti - Columbia SC, US
Mitzi Nagarkatti - Columbia SC, US

Assignee:

University of South Carolina - Columbia SC

International Classification:

A61K 31/05
A61P 31/00

US Classification:

514733

Abstract:

Cannabinoids are known to interact with CB1 and CB2 receptors expressed in the nervous and immune systems mediating a wide range of effects, including anti-inflammatory properties. However, cannabinoids that bind are also psychoactive thereby limiting their clinical use. Cannabidiol (CBD) is the most abundant nonpsychotropic plant cannabinoid but has not been studied as extensively as Δ-tetrahydrocannabinol (THC). The present disclosure reports the immunosuppressive properties of CBD and demonstrates that CBD induces apoptosis in thymocytes and splenocytes and inhibits the proliferative responsiveness of T and B cells. This indicates that CB2 selective agonists, devoid of psychotropic effect, may serve as novel anti-inflammatory/immunosuppressive agents.

US Patent:

20120302646, Nov 29, 2012

Filed:

Jul 31, 2012

Appl. No.:

13/562750

Inventors:

Prakash S. Nagarkatti - Columbia SC, US
Mitzi Nagarkatti - Columbia SC, US

Assignee:

University of South Carolina - Columbia SC

International Classification:

A61K 31/05
A61P 1/16
A61P 37/00

US Classification:

514733

Abstract:

Cannabinoids are known to interact with CB1 and CB2 receptors expressed in the nervous and immune systems mediating a wide range of effects, including anti-inflammatory properties. However, cannabinoids that bind CB1 are also psychoactive thereby limiting their clinical use. Cannabidiol (CBD) is the most abundant nonpsychotropic plant cannabinoid but has not been studied as extensively as Δ-tetrahydrocannabinol (THC). The present disclosure reports the immunosuppressive properties of CBD and demonstrates that CBD induces apoptosis in thymocytes and splenocytes and inhibits the proliferative responsiveness of T and B cells. This indicates that CB2 selective agonists, devoid of psychotropic effect, may serve as novel anti-inflammatory/immunosuppressive agents.

US Patent:

20200268848, Aug 27, 2020

Filed:

Dec 17, 2019

Appl. No.:

16/717340

Inventors:

- COLUMBIA SC, US
Prakash Nagarkatti - Columbia SC, US
Mitzi Nagarkatti - Columbia SC, US

International Classification:

A61K 38/18
A61K 31/7105
C12N 15/113
C07K 16/28
A61P 29/00

Abstract:

The present application relates to induction of a Treg phenotype in mammalian naïve CD4+ T cells. In certain embodiments, the methods and compositions described can be applied as methods to treat autoimmune disorders or transplant complications (e.g., lupus and graft-versus-host disease) and may be used in combination with, but do not require, systemic immune suppression, such as a chemotherapeutic agent. In particular, embodiments of the disclosure can utilize transforming growth factor-beta 2 (TGFB2), molecules that stimulate the production of TGFB2, inhibitors of molecules that suppress production of TGFB2, or molecules that effect the function of TGFB2 to induce a Treg phenotype in naïve CD4+ T cells from a mammal. Provided herein are embodiments and examples demonstrating the production of Treg cells, as well as the application of Treg cells in modulating the inflammatory response present in certain diseases.

US Patent:

20200254020, Aug 13, 2020

Filed:

Dec 4, 2019

Appl. No.:

16/703329

Inventors:

- Columbia SC, US
Prakash Nagarkatti - Columbia SC, US
Mitzi Nagarkatti - Columbia SC, US

International Classification:

A61K 35/17
C12N 15/113
A61K 31/4709
A61P 25/00

Abstract:

The present disclosure is directed to compositions and methods to treat the inflammatory response present in certain diseases and illnesses by modifying a dysregulation of one or more genes associated with the Wnt/β-catenin signaling pathway. Embodiments of the disclosure can provide methods for treating an inflammatory response in a patient by identifying the inflammatory response and modifying the inflammatory response.

US Patent:

20190112609, Apr 18, 2019

Filed:

Apr 30, 2018

Appl. No.:

15/966171

Inventors:

- Columbia SC, US
Prakash Nagarkatti - Columbia SC, US
Mitzi Nagarkatti - Columbia SC, US

International Classification:

C12N 15/113
A61P 3/04

Abstract:

MicroRNA-30 is identified as being dysregulated in adipose tissue macrophages during obesity and can be used in treatment of disease in which adipose tissue macrophage polarization dysregulation plays a part. Increased concentration of microRNA-30, e.g., via pharmaceutical delivery, can decrease the polarization of macrophages, and in particular adipose tissue macrophages, to inflammatory M1 phenotype and can decrease expression of pro-inflammatory cytokines. One or more members of the miR-30 family can be utilized in the methods. Methods can be beneficial in treatment of a large number of inflammatory diseases including obesity, diabetes, cancer, autoimmune, etc.